ACADIA Pharmaceuticals share price logo

ACADIA Pharmaceuticals

NASDAQ: ACAD

Mid Cap

$20.59

-0.17

(-0.82%)

as on

ACADIA Pharmaceuticals Stock Performance

as on October 31, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $20.49
    $21.01
    downward going graph

    0.49%

    Downside

    2.04%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $18.39
    $30.96
    downward going graph

    10.68%

    Downside

    50.36%

    Upside

    downward going graph

ACADIA Pharmaceuticals share price movements today

Previous Close
$20.76
Open
$20.77
Volume
620.6K
Market Cap
$3.5B
Day's Low - High
$20.49 - $21.01
52 Week Low - High
$18.39 - $30.96

ACADIA Pharmaceuticals Historical Returns

1 Month Return
+ 3.03 %
3 Month Return
-21.81 %
1 Year Return
-8.71 %
3 Year Return
-6.61 %
5 Year Return
+ 15.65 %

ACADIA Pharmaceuticals Stock Fundamentals & Key Indicators

Check ACADIA Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.5B

EPS (TTM)

2.25

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.13%

PE Ratio (TTM)

9.03

Industry PE ratio

-7.01

PEG Ratio

0.13

EBITDA

116.1M

Revenue (TTM)

1.1B

Profit Margin

91.13%

Return On Equity TTM

32.39%

ACADIA Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ACADIA Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$3.5B15.65%9.0391.13%0.00%
Neutral$85.5B-35.47%-26.84-12.57%0.00%
StrongBuy$134.2B192.00%30.5886.04%0.00%
Buy$83.7B27.94%19.4284.86%0.45%

Stock Returns calculator for ACADIA Pharmaceuticals Stock including INR - Dollar returns

The ACADIA Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

ACADIA Pharmaceuticals investment value today

Current value as on today

₹96,900

Returns

-₹3,100

(-3.1%)

Returns from ACADIA Pharmaceuticals Stock

-₹9,455 (-9.45%)

Dollar Impact

₹6,354 (+6.35%)

Analyst Recommendation on ACADIA Pharmaceuticals Stock

Based on 10 analysts

BUY

70.00%

Buy

30.00%

Hold

0.00%

Sell

Based on 10 analysts, 70% of analysts recommend a 'BUY' rating for ACADIA Pharmaceuticals. Average target price of $30.53

ACADIA Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on ACADIA Pharmaceuticals.

What analysts predicted

32.56%UPSIDE

Target Price

$30.53

Current Price

$20.59

Analyzed by

10 Analysts

High

$37

Target

$30.53

Low

$23

ACADIA Pharmaceuticals target price $30.53, a slight upside of 32.56% compared to current price of $20.59. According to 10 analysts rating.

Indian Investors' Interest in ACADIA Pharmaceuticals Stock

Search interest for ACADIA Pharmaceuticals Stock has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-30% versus previous 30 day period

ACADIA Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
205
241
250
259
244
264
278
283
268
307
Gross Profit
182
223
231
237
223
243
256
257
243
279
Operating Income
15
30
31
153
19
32
35
17
-4
37
EBITDA
26
39
41
12
30
43
47
29
6
32
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
5
2
2
5
2
2
2
2
2
3
Income Before Tax
21
37
38
161
27
40
44
26
3
46
Income Tax Expense
4
3
6
17
8
13
-27
-247
0
14
Net Income
16
33
32
143
18
26
71
273
3
31
Net Profit Margin
88.85%
92.47%
92.47%
91.60%
91.65%
92.16%
92.23%
90.77%
90.75%
90.81%

ACADIA Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
124
223
339
441
484
517
726
957
1,071
Gross Profit
111
205
319
421
465
507
680
875
982
Operating Income
-292
-247
-246
-286
-170
-223
-73
230
104
EBITDA
-289
-244
-243
-283
-164
-211
-45
100
150
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
2
3
2
2
3
2
5
15
11
Income Before Tax
-288
-243
-234
-280
-167
-213
-51
258
138
Income Tax Expense
1
1
0
0
0
2
10
31
-252
Net Income
-289
-245
-235
-281
-167
-215
-61
226
391
Net Profit Margin
89.54%
91.81%
94.22%
95.35%
96.05%
98.03%
93.70%
91.46%
91.69%

ACADIA Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
16
33
32
143
18
26
71
273
3
35
Operating Cash Flow
29
25
63
40
20
63
74
-48
33
134
Investing Cash Flow
-14
-56
-82
122
-124
-43
-79
-55
66
57
Financing Cash Flow
1
3
0
1
1
15
9
22
4
14
Change in Cash
16
-27
-18
164
-101
36
4
-80
104
207

ACADIA Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-289
-245
-235
-281
-167
-215
-61
226
391
Operating Cash Flow
-217
-167
-151
-136
-125
-114
16
157
109
Investing Cash Flow
92
-71
-165
192
-71
73
31
-30
-302
Financing Cash Flow
31
306
371
80
18
8
25
6
49
Change in Cash
-94
67
54
137
-178
-32
73
133
-141

Global Institutional Holdings in ACADIA Pharmaceuticals

Check out the Institutions with significant holdings in ACADIA Pharmaceuticals.

Funds
Holdings
Felix Baker
24.91%
iShares
9.31%
Vanguard
7.02%
VANGUARD INDEX FUNDS
5.91%
SPDR
2.89%

ACADIA Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 25 September

    Fri, 06:07 PM

    -

    Deutsche Bank lowers Acadia's price target to $31, citing Phase 2 trial miss for remlifanserin in Alzheimer's disease psychosis.

Insights on ACADIA Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 3.63M → 31.50M (in $), with an average increase of 88.5% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 268.06M → 307.95M (in $), with an average increase of 13.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ACAD stock has moved up by 5.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 192.3% return, outperforming this stock by 201.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 720.2% return, outperforming this stock by 728.7%

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
OrganisationACADIA Pharmaceuticals
Headquarters12830 El Camino Real, San Diego, CA, 92130, US
IndustryBiotechnology
CEOCatherine E. Owen Adams

Key Management of ACADIA Pharmaceuticals

Name

Title

Ms. Catherine E. Owen Adams

CEO & Director

Mr. Mark C. Schneyer

Executive VP & CFO

Ms. Jennifer J. Rhodes J.D.

Executive VP, Chief Legal Officer & Secretary

FAQs

What is ACADIA Pharmaceuticals share price today?

ACADIA Pharmaceuticals share price today is $20.59 as on at the close of the market. ACADIA Pharmaceuticals share today touched a day high of $21.01 and a low of $20.49.

What is the 52 week high and 52 week low for ACADIA Pharmaceuticals share?

ACADIA Pharmaceuticals share touched a 52 week high of $30.96 on and a 52 week low of $18.39 on . ACADIA Pharmaceuticals stock price today i.e. is closed at $20.59,which is 33.49% down from its 52 week high and 11.96% up from its 52 week low.

What is ACADIA Pharmaceuticals's market capitalisation today?

ACADIA Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in ACADIA Pharmaceuticals Stock (ACAD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for ACADIA Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy ACADIA Pharmaceuticals Stock (ACAD) from India?

Indian investors can start investing in ACADIA Pharmaceuticals (ACAD) shares with as little as ₹94.94999694824219 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in ACADIA Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on ACADIA Pharmaceuticals share’s latest price of $20.59 as on October 31, 2026 at 8:46 am IST, you will get 0.4857 shares of ACADIA Pharmaceuticals. Learn more about fractional shares .

What are the returns that ACADIA Pharmaceuticals has given to Indian investors in the last 5 years?

ACADIA Pharmaceuticals stock has given 15.65% share price returns and 27.22% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?